English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In the last 25 years, Prostate Specific Antigen (PSA) screening has resulted in a large gap between the likelihood of being diagnosed with and of dying of prostate cancer, leading to the clinical problems of overdiagnosis and overtreatment. Despite the favorable outcomes reported for active surveillance, its clinical use is limited, with .90% of menintheUSdiagnosedwithpotentiallyindolent disease undergoing immediate treatment with radiation or surgery. We have designed a novelstrategy of molecularprofiling of prostate cancers,allowinganassessmentoftumoraggres

A genomic approach to active surveillance: a step toward precision medicine